Back to top
more

Ocugen (OCGN)

(Delayed Data from NSDQ)

$0.99 USD

0.99
4,396,501

+0.04 (4.40%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $1.00 +0.01 (0.82%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Ocugen to Begin Phase III Study on Eye Drug in Canada, Stock Up

by Zacks Equity Research

OCGN receives Health Canada's No Objection Letter to begin a phase III study on OCU400 for treating retinitis pigmentosa. Shares rise.

Is Ocugen (OCGN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Ocugen (OCGN) and Organon (OGN) have performed compared to their sector so far this year.

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Atossa Genetics Inc. (ATOS) and Ocugen (OCGN) have performed compared to their sector so far this year.

Ocugen (OCGN) Skyrockets 209.6% Year to Date: Heres Why

by Zacks Equity Research

Ocugen's (OCGN) shares rise significantly in the year-to-date period on positive progress with its promising pipeline candidates.

Is Bicycle Therapeutics (BCYC) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Bicycle Therapeutics PLC Sponsored ADR (BCYC) and Ocugen (OCGN) have performed compared to their sector so far this year.

Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Ocugen (OCGN) is expected to provide updates regarding the developmental program of its lead candidate, OCU400, for two rare retinal diseases in the first-quarter earnings release.

Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study

by Zacks Equity Research

Ocugen (OCGN) stock gains as the DSMB for the phase I/II study of OCU410 approves the initiation of dosing with the medium dose of OCU410 in the dose-escalation phase of the GA study.

Derek Lewis headshot

Ocugen Q2 Preview: Rebound Quarter Inbound?

by Derek Lewis

Ocugen shares have struggled over the last year, declining more than 60% in value and vastly underperforming the S&P 500.

Implied Volatility Surging for Ocugen (OCGN) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Ocugen (OCGN) stock based on the movements in the options market lately.

Ocugen (OCGN) Covaxin Studies Clinical Hold Lifted by FDA

by Zacks Equity Research

Ocugen (OCGN) gets respite after the FDA lifts the clinical hold on the company's phase II/III study, OCU-002, for Covaxin (BBV152).

Ocugen (OCGN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ocugen (OCGN) delivered earnings and revenue surprises of -280% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: SRRA Surges on GSK Buyout, HALO Offers Update & More

by Zacks Equity Research

Acquisition news from GlaxoSmithKline (GSK) and HALO are a few key highlights from the biotech sector during the past week.

Ocugen (OCGN) Stock Down as FDA Puts Hold on Covaxin Study

by Zacks Equity Research

Ocugen (OCGN) is conducting the OCU-002 study to support its BLA for the approval of Covaxin in the United States. The FDA places a clinical hold on this study.

    The Zacks Analyst Blog Highlights Ocugen, Voyager Therapeutics, BioNTech, Regeneron and Gilead Sciences

    by Zacks Equity Research

    Ocugen, Voyager Therapeutics, BioNTech, Regeneron and Gilead Sciences are included in this blog.

    Biotech Stock Roundup: OCGN Down on Update, VYGR Surges on Deal & Other Updates

    by Zacks Equity Research

    Regulatory and other details from Ocugen (OCGN) as well as Voyager (VYGR) are a few key highlights from the biotech sector during the past week.

    Ocugen (OCGN) Down 23% With FDA Denial of COVID Vaccine EUA

    by Zacks Equity Research

    The FDA turns down an emergency use authorization request from Ocugen (OCGN) to use its COVID-19 vaccine Covaxin in pediatric population. Stock depreciates.

    Should You Invest in the SPDR S&P Biotech ETF (XBI)?

    by Zacks Equity Research

    Sector ETF report for XBI

    Ocugen's (OCGN) COVID-19 Booster Effective Against Omicron

    by Zacks Equity Research

    Ocugen's (OCGN) India-based partner announces robust neutralizing antibody responses against Omicron and Delta variants, following the administration of the booster dose of COVID-19 vaccine, Covaxin.

    Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

    by Zacks Equity Research

    Smart Beta ETF report for XBI

    Ocugen (OCGN) Up on Bharat Biotech's Data in Pediatric Group

    by Zacks Equity Research

    Ocugen (OCGN) gains on Bharat Biotech's positive results from a study in the pediatric population.

    Should You Invest in the SPDR S&P Biotech ETF (XBI)?

    by Zacks Equity Research

    Sector ETF report for XBI

    Company News for Oct 6, 2021

    by Zacks Equity Research

    Companies in The News Are: PEP, JNJ, OCGN, SPWR.

    Do Options Traders Know Something About Ocugen (OCGN) Stock We Don't?

    by Zacks Equity Research

    Investors need to pay close attention to Ocugen (OCGN) stock based on the movements in the options market lately.

    Implied Volatility Surging for Ocugen (OCGN) Stock Options

    by Zacks Equity Research

    Investors need to pay close attention to Ocugen (OCGN) stock based on the movements in the options market lately.

    Ocugen's (OCGN) Q2 Earnings Miss Estimates, Stock Down

    by Zacks Equity Research

    Ocugen (OCGN) miss earnings estimates in the second quarter of 2021. Stock down.